FDA Revises Guidance on Paclitaxel-Coated Devices for Peripheral Arterial Disease Treatment

In a recent announcement, the US Food and Drug Administration (FDA) revised its guidance on paclitaxel-coated devices used in the treatment of peripheral arterial disease (PAD). The new guidance states that warnings about excess mortality risk associated with these devices are no longer supported based on a comprehensive review of trial data. This update brings relief to patients and healthcare providers, expanding treatment options and ensuring patient safety.

A Comprehensive Review of Trial Data

The FDA’s decision is based on an updated analysis of the totality of available data and thorough assessments of various studies. The review encompassed all paclitaxel-coated devices, including different models, lots, and unique device identifiers. The agency’s analysis revealed that there is no evidence of excess mortality risk associated with paclitaxel-coated devices used to treat PAD.

A Journey of Discovery

The concerns regarding mortality risk first surfaced in August 2019 when the FDA issued a communication highlighting a late mortality signal observed in patients treated for PAD in the femoropopliteal artery using paclitaxel-coated balloons and paclitaxel-eluting stents. However, subsequent individual randomized trials and retrospective cohort studies did not demonstrate such signals, leaving investigators perplexed about the cause.

To address these concerns, the FDA collaborated with device manufacturers, leading to an updated meta-analysis that included additional studies and longer-term follow-up data. The studies involved patient follow-up ranging from 2 to 5 years, with most studies extending up to 5 years. The FDA’s clinicians and statisticians conducted a thorough review of this updated data and concluded that the use of paclitaxel-coated devices does not pose a late mortality risk.

Further Analyses and Ongoing Studies

In addition to the updated meta-analysis, the FDA reviewed several other studies, including the SWEDEPAD trial interim analysis, VOYAGER PAD, the German BARMER Health Insurance study, the U.S. Veterans Health Administration study, and the Medicare SAFE-PAD study. These analyses, with follow-up ranging from 1.7 to 3.5 years, also found no risk for late mortality associated with paclitaxel-coated devices.

While these findings provide significant reassurance, the FDA acknowledges that longer-term follow-up is still ongoing for some of these studies. Continued monitoring and evaluation of real-world data will be crucial to ensuring the ongoing safety and effectiveness of these devices.

The revised guidance from the FDA represents a significant milestone in the field of peripheral arterial disease treatment. Patients can now have access to a wider range of treatment options, while healthcare providers can make informed decisions based on the latest evidence. This update underscores the FDA’s commitment to patient safety and its dedication to continuous evaluation and improvement of medical device interventions.